SARS‐CoV‐2 humoral responses following booster BNT162b2 vaccination in patients with B‐cell malignancies
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26669
Abstract: Patients with B‐cell malignancies have suboptimal immune responses to SARS‐CoV‐2 vaccination and are a high‐risk population for severe COVID19 disease. We evaluated the effect of a third booster BNT162b2 vaccine on the kinetics of anti‐… read more here.
Keywords: patients cell; booster bnt162b2; cell malignancies; humoral responses ... See more keywords
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Hematology"
DOI: 10.1007/s00277-020-04221-0
Abstract: The B cell surface antigen CD19 is a target for treating B cell malignancies, such as B cell precursor acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma. The BiTE® immuno-oncology platform includes blinatumomab, which is… read more here.
Keywords: bispecific cell; cell malignancies; immuno oncology; cell engager ... See more keywords
Senescent/Exhausted Phenotype of CAR T Cells and Induction of Immunoregulatory Environment Correlate with Reduced Response to CAR T Cell Therapy in Relapsed/Refractory B Cell Malignancies
Sign Up to like & getrecommendations! Published in 2020 at "Biology of Blood and Marrow Transplantation"
DOI: 10.1016/j.bbmt.2019.12.394
Abstract: Chimeric antigen receptor (CAR) T cells have shown promising results in patients (pts) with B cell malignancies, yet approximately 60% of pts with diffuse large B cell lymphoma (DLBCL) will relapse. Therefore, future efforts are… read more here.
Keywords: relapsed refractory; response; cell malignancies; car cells ... See more keywords
Design and Optimization of Thienopyrimidine Derivatives as Potent and Selective PI3Kδ Inhibitors for the Treatment of B-Cell Malignancies.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.2c00530
Abstract: Phosphoinositide 3-kinase δ (PI3Kδ) plays a critical role in B lymphocyte (B-cell) development and activation and has been a validated target for the treatment of B-cell malignancies. Herein, we report a series of thienopyrimidine derivatives… read more here.
Keywords: pi3k; cell; treatment cell; thienopyrimidine derivatives ... See more keywords
Mouse Models in the Study of Mature B-Cell Malignancies.
Sign Up to like & getrecommendations! Published in 2020 at "Cold Spring Harbor perspectives in medicine"
DOI: 10.1101/cshperspect.a034827
Abstract: Over the past two decades, genomic analyses of several B-cell lymphoma entities have identified a large number of genes that are recurrently mutated, suggesting that their aberrant function promotes lymphomagenesis. For many of those genes,… read more here.
Keywords: mouse models; cell malignancies; mature cell; cell ... See more keywords
A non‐covalent inhibitor XMU‐MP‐3 overrides ibrutinib‐resistant BtkC481S mutation in B‐cell malignancies
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Pharmacology"
DOI: 10.1111/bph.14809
Abstract: Bruton's tyrosine kinase (BTK) plays a key role in B‐cell receptor signalling by regulating cell proliferation and survival in various B‐cell malignancies. Covalent low‐MW BTK kinase inhibitors have shown impressive clinical efficacy in B‐cell malignancies.… read more here.
Keywords: resistant btkc481s; btkc481s mutation; cell malignancies; ibrutinib resistant ... See more keywords
Low Expression of CD5 and CD6 Is Associated with Poor Overall Survival for Patients with T-Cell Malignancies
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Oncology"
DOI: 10.1155/2022/2787426
Abstract: Background T-cell malignancies (TCMs), including T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma (TCL), are highly aggressive and have a poor prognosis. To further understand prognostic stratifications and to design targeted therapies, this study aims… read more here.
Keywords: cd5 cd6; expression; cd6; associated poor ... See more keywords
Abstract CT128: Phase 1 study of HSK29116, a Bruton tyrosine kinase (BTK) proteolysis-targeting chimera (PROTAC) agent, in patients with relapsed or refractory B-cell malignancies
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct128
Abstract: BACKGROUND: BTK, a non-receptor kinase in the B-cell receptor signaling pathway, plays an essential role in B-cell development and differentiation. BTK is critical for malignant B-cell survival. Oral BTK inhibitors (BTKis), standard treatments for patients… read more here.
Keywords: cell; kinase; phase; protac ... See more keywords
Parsaclisib Has Activity in Patients with B-cell Malignancies.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2019-031
Abstract: A next-generation PI3Kδ inhibitor achieved objective responses and long-term tolerability in NHL. read more here.
Keywords: parsaclisib activity; cell malignancies; patients cell; activity patients ... See more keywords
T-cell Malignancies Can Be Targeted by Bispecific Antibody Treatments.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2021-042
Abstract: Bispecific antibodies targeting malignant T cells showed selectivity and efficacy in vitro and in vivo. read more here.
Keywords: antibody treatments; bispecific antibody; targeted bispecific; malignancies targeted ... See more keywords
Primary Small Cell Malignancies of the Breast: Are They Rare Malignancies?
Sign Up to like & getrecommendations! Published in 2021 at "Acta cytologica"
DOI: 10.1159/000520875
Abstract: In contrast with the other organs such as the lung, small cell tumors have been less studied in the breast due to their relatively less frequency. Although rare, neuroendocrine neoplasms, some lymphomas, and some small… read more here.
Keywords: small cell; breast rare; cell; primary small ... See more keywords